Dogs are some of the most endearing creatures on the planet and one of the most tragic things about them is their short lives, at least when compared to humans. Depending on the breed, they can live from 7 to 15 years, on average. Scientists are currently working to extend that period by addressing certain health issues that develop in canines during their lifetime.
The effort to extend the lifespan of man’s best friends is being done by the startup Rejuvenate, which is run by George Church. Church is the famous Harvard geneticist who pioneered CRISPR, thus starting the whole gene-editing renaissance that is currently trending. If it works on dogs, the thinking is that perhaps it can work on humans too, the MIT Technology Review reports.
Rejuvenate is basically working to tweak the genes of dogs to hopefully double their lifespan or increase it even further. By making dogs younger or, at least, extending the amount of time they spend being young, the thought is that it will help give them more time before health issues start hitting them.
Now, it’s worth pointing out that this can be a touchy issue. Although the idea of extending the lives of dogs might seem great, the idea of scientists experimenting on dogs can be horrific for canine lovers.
On the other hand, there are already plenty of questionable practices that involve dogs such as cloning right now, Futurism notes. Perhaps the idea of being able to live with their beloved furry pals might just be palatable enough for pet owners to ignore the potential harm that can be done before this goal is achieved.
There is also the matter of the potential benefits that this breakthrough could have for humans. At this point, the average lifespan of people ranges from 60 to 80 years. If Rejuvenate succeeds, this could go up to 120 years, at least.


FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Neuralink Expands Brain Implant Trials with 12 Global Patients
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast
Tabletop particle accelerator could transform medicine and materials science
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 



